<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690287</url>
  </required_header>
  <id_info>
    <org_study_id>D0280C00014</org_study_id>
    <nct_id>NCT00690287</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients</brief_title>
  <official_title>A Dose-Ranging Study to Evaluate Fasting and Postprandial P-Glucose, Safety and Tolerability After Oral Single, B.I.D and Q.I.D Dosing of AZD6370 in Patients With Diabetes Mellitus: a Randomized, Single-Blind, Placebo-Controlled, Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of AZD6370 on blood sugar and to study
      safety and tolerability in patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic variables</measure>
    <time_frame>Blood samples taken repeatedly during 24 hours on study day sessions</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables</measure>
    <time_frame>Blood samples taken repeatedly during 24 hours on study day sessions</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables</measure>
    <time_frame>Blood samples taken repeatedly during 24 hours on study day sessions</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Part A, arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo together with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo without food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, arm1, 2, and 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD6370 dose x mg o.d.
dose x/2 mg b.i.d.
dose x/4 mg q.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4) Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6370</intervention_name>
    <description>Oral single doses a+b+c, o.d., suspension</description>
    <arm_group_label>Part A, arm 1</arm_group_label>
    <arm_group_label>Part A, arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6370</intervention_name>
    <description>Oral single dose, o.d., b.i.d. and q.i.d., suspension</description>
    <arm_group_label>Part B, arm1, 2, and 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Part B, arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treated with diet or metformin. Stable glycemic control indicated by no changed
             treatment within 3 months

          -  Diabetes Mellitus diagnosis &lt;5 years

        Exclusion Criteria:

          -  Clinically significant illness or clinically relevant trauma, as judged by the
             investigator, within two weeks before the first administration of the investigational
             product

          -  Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis
             results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klas Malmberg, MD, PhD, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Mölndal, SE-431 83 Mölndal, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Kühn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles AB, Phase I Services, Strandbodgatan 1, SE-753 23 Uppsala, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>January 10, 2012</last_update_submitted>
  <last_update_submitted_qc>January 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

